Life Sciences Tools and Services
Company Overview of Chromocell Corporation
Chromocell Corporation, a life sciences company, discovers and develops flavors and functional ingredients, and therapeutics based on Chromovert technology. Its Chromovert technology enables the company to use naturally occurring systems that mimic human biology as a part of its discovery platform to provide practical solutions to problems in food and pharmaceuticals. The company specializes in molecular and cell biology, assay development, screening, and medicinal chemistry areas. It also focuses on identifying new drugs/therapeutic compounds for pain relief, anxiety treatment, and treatment of respiratory disorders. In addition, Chromocell Corporation develops flavor ingredients and natura...
685 U.S. Highway One
North Brunswick, NJ 08902
Founded in 2002
Key Executives for Chromocell Corporation
Head of Business Development and Associate Director
Senior Vice President of Therapeutics
Senior Vice President of Flavors and Natural Products
Vice President of Legal Affairs and Corporate Development
Compensation as of Fiscal Year 2016.
Chromocell Corporation Key Developments
Astellas Pharma and Chromocell Enter into Drug Development Collaboration for Neuropathic Pain
Oct 1 15
Astellas Pharma, Inc. and Chromocell Corporation have entered into a collaboration to develop and commercialise treatments for neuropathic pain and other pain conditions, the companies said in a statement. Under the agreement, Astellas receives global rights to commercialise pain treatment CC8464, as well as product candidates identified through Chromocell's Chromovert technology platform. Chromocell will receive an upfront payment of 15 million and is eligible to receive over 500 million in development and commercial milestones, as well as double-digit sales royalties from CC8464. In addition, Chromocell may suggest and initiate studies for additional indications, such as rare diseases and non-oral formulations of the drug candidate. Astellas would be eligible for inclusion into these additional developments, which would result in further payments for Chromocell and US co-promotion rights in some cases.
Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain
Sep 30 15
Astellas Pharma Inc. and Chromocell Corporation announced that they have entered into a license and collaboration agreement for the development and commercialization of therapeutics to treat neuropathic and other pain conditions. Astellas obtains worldwide rights to commercialize CC8464 and back-up drug candidates to treat pain that have been identified through Chromocell's Chromovert® technology platform. Chromocell receives $15 million as an up-front payment and is eligible to receive over $500 million, including development and commercial milestones, as well as double digit royalties on sales if CC8464 is successfully commercialized. Chromocell will conduct all development of CC8464 through the initial Phase 2a proof-of-concept clinical trial in neuropathic pain. Astellas will lead all further development activities through to commercialization of CC8464 for the treatment of peripheral neuropathic pain. Aside from those development activities, Chromocell may propose, and may initiate, studies for certain additional indications such as rare diseases and non-oral formulations of the drug candidate. Astellas has the right to opt-in for development for such additional indications, which triggers additional payments to Chromocell, and, in certain cases, co-promotion rights in the U.S. NaV1.7 is an ion channel, involved in the transmission of pain. Chromocell's lead compound, CC8464, is an oral, peripherally-acting inhibitor of NaV1.7, which may prove to be efficacious in several large unmet or poorly served chronic pain markets as well as rare, currently untreated diseases. Chromocell anticipates filing an IND for CC8464 in early 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|